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OBJECTIVE — Vasculoprotective endothelial progenitor cells (EPCs) are regulated by stro-
mal-derived factor-1 (SDF-1) and are reduced in type 2 diabetes. Because SDF-1 is a
substrate of dipeptidyl-peptidase-4 (DPP-4), we investigated whether the DPP-4 inhibitor sita-
gliptin modulates EPC levels in type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — This was a controlled, nonrandomized clin-
ical trial comparing 4-week sitagliptin (n  16) versus no additional treatment (n  16) in
addition to metformin and/or secretagogues in type 2 diabetic patients. We determined circu-
lating EPC levels and plasma concentrations of SDF-1, monocyte chemoattractant protein-1
(MCP-1), vascular endothelial growth factor (VEGF), and nitrites/nitrates.
RESULTS — There was no difference in clinical baseline data between the sitagliptin and
control arms. After 4 weeks, as compared with control subjects, patients receiving sitagliptin
showed a signiﬁcant increase in EPCs and SDF-1 and a decrease in MCP-1.
CONCLUSIONS — Sitagliptin increases circulating EPCs in type 2 diabetic patients with
concomitant upregulation of SDF-1. This ancillary effect of DPP-4 inhibition might have
potential favorable cardiovascular implications.
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E
ndothelial progenitor cells (EPCs)
provide vascular protection by means
of endothelial repair and neoangio-
genesis (1). Type 2 diabetes, especially in
the presence of macrovascular complica-
tions, is associated with reduced circulat-
ing EPCs (2), which in turn has been
linked to incident cardiovascular disease
(3,4). Reduced EPCs are considered a
novel pathogenic mechanism of vascular
disease and a biomarker of vascular risk
(5). For these reasons, ways to stimulate
EPCs in diabetes are actively pursued.
The dipeptidyl peptidase-4 (DPP-4) in-
hibitor sitagliptin blocks degradation of
incretins by DPP-4. Among other physio-
logical substrates of DPP-4 is stromal-
derived factor-1 (SDF-1) (6), a
chemokine that stimulates bone marrow
mobilization of EPCs (7). We have re-
cently reported that reduction of circulat-
ing progenitor cells in diabetes is at least
in part attributable to a bone marrow de-
fect (8). Herein, we hypothesize that
inhibitionofDPP-4mobilizesEPCsinpa-
tients with type 2 diabetes, by protecting
SDF-1 from enzymatic degradation.
RESEARCH DESIGN AND
METHODS— A detailed description
of methods can be found in the on-
line appendix available at http://care.
diabetesjournals.org/cgi/content/full/
dc10-0187/DC1. This was a controlled,
nonrandomized, 4-week trial comparing
100 mg sitagliptin versus no additional
treatment on top of metformin and/or
secretagogues in poorly controlled type 2
diabetic patients. The protocol was ap-
provedbythePadovaUniversityHospital
ethics committee. At baseline and after 4
weeks, blood samples were drawn for de-
termination of circulating EPCs and
plasma concentrations of SDF-1, vascu-
lar endothelial growth factor (VEGF),
monocyte chemoattractant protein-1
(MCP-1), and nitrite/nitrate (NOx). EPCs
were deﬁned as CD34
KDR
 cells and
measuredbyﬂowcytometryaspreviously
described (2). Total CD34
 cell count
was also determined, and CD34
 or
CD34
KDR
 cells were assayed for ex-
pression of CXCR4. SDF-1, VEGF, and
MCP-1 were measured using multiplex
suspension arrays. NOx was measured
with an enzymatic assay. Plasma DPP-4
activity was measured as conversion of
the substrate H-Gly-Pro-AMC to a ﬂuo-
rescent product. Data are expressed as
means  SE, and statistical signiﬁcance
was accepted at P  0.05.
RESULTS— Clinical data of the sita-
gliptin and control groups are reported in
online appendix Table 1, and there was
no signiﬁcant difference between the
groups. The sample was representative of
a 65-year-old diabetic population with
mildlyuncontrolleddiseaseandamoder-
ate prevalence of complications.
Therapywithsitagliptin100mgdaily
was well tolerated, and the patients re-
ported no adverse effects. DPP-4 inhibi-
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reduction of free plasma DPP-4 activity in
thesitagliptingroup,whilenochangewas
found in the control group (Fig. 1A).
Progenitorcellcountswerenotdiffer-
ent at baseline between the two groups.
In the whole cohort, EPCs were signiﬁ-
cantly negatively correlated with baseline
plasmaglucose(r0.445;P0.011).
CirculatingEPCsincreasedabouttwofold
inthesitagliptingroup,andremainedun-
changed in the control group (Fig. 1B).
The correlation between plasma glucose
and EPCs was lost after 4 weeks (online
appendix Fig. 1). Total CD34
 cell count
was unaffected in both groups (Fig. 1C).
In the sitagliptin group, plasma concen-
trationsofSDF-1increasedby50%(P
0.001), while MCP-1 concentrations de-
creased by 25% (P  0.01) and VEGF
levels remained unchanged. No signiﬁ-
cantdifferencesinbaselineversus4-week
concentrations of SDF-1, MCP-1, and
VEGFwereobservedinthecontrolgroup
(Fig. 1D–F). We found no signiﬁcant
modiﬁcation of NOx concentrations in
both groups. Online appendix Table 2
contains rough data showing that be-
tween-group differences of EPCs, SDF-1,
and MCP-1 were statistically signiﬁcant. To
explain the differential effects of sitagliptin
on CD34
 versus CD34
KDR
 cells, we
show that SDF-1 receptor CXCR4 was
expressed on 17% of CD34
 cells and on
63%ofCD34
KDR
cells(onlineappen-
dix Fig. 2).
CONCLUSIONS— In this study, we
show for the ﬁrst time that sitagliptin in-
creases EPCs in type 2 diabetic patients,
as an ancillary effect of DPP-4 inhibition,
possiblymediatedbytheSDF-1/CXCR4
axis.
Experimental studies demonstrate
that EPCs stimulate endothelial repair
and angiogenesis (1). These cells are re-
ducedindiabeticpatientsatanearlystage
and are further impaired in patients with
macro-/microvascular complications
(2,8,9). Low baseline progenitor cell lev-
els predict adverse outcomes of macro-
and microangiopathy (3,4,10), and EPC
reductionisnowconsideredanovelroute
to development and worsening of diabe-
tes complications. In response to isch-
emia, SDF-1 is upregulated and, upon
bindingtoitsreceptorCXCR4,stimulates
the bone marrow to release EPCs that are
eventually recruited at ischemic sites (7).
In diabetic animals a blunted SDF-1 re-
sponse to ischemia is associated with in-
hibited progenitor cell release from the
bone marrow and defective postischemic
angiogenesis (11). Given that SDF-1 is a
physiological substrate of DPP-4 (6),
DPP-4 inhibition is expected to increase
circulating SDF-1 levels, which in turn
could affect EPC-mediate cardiovascular
repair, as shown by Zaruba et al. (12) in
mice with myocardial infarction.
We report that a 4-week therapy with
100 mg oral sitagliptin increased plasma
SDF-1 concentration and circulating
EPCs. The most straightforward interpre-
tation is that DPP-4 inhibition raised
SDF-1 concentrations, which mobilized
EPC from the bone marrow. An alterna-
tive explanation is that glucose lowering
per se improved EPC bioavailability
(11,13). However, the short duration of
thepresenttrialandthelossofcorrelation
betweenplasmaglucoseandEPClevelsat
study end seem to argue against this hy-
pothesis. Finally, the increased glucagon-
like peptide 1 concentrations achieved by
DPP-4 inhibition might have determined
an effect on EPCs through endothelial ni-
tric oxide synthase activation (14), which
is essential for EPC mobilization (15). So
far, the absence of changes in nitrate/
nitrite levels after sitagliptin does not
support this hypothesis. Reduced con-
centrations of the proinﬂammatory che-
mokine MCP-1 achieved by sitagliptin is
another potential mechanism for the re-
stored levels of circulating EPCs. The
mildandnotsigniﬁcantactionofsitaglip-
tin on CD34
 cells is to be attributed to
the much lower expression of CXCR4
on these cells than on CD34
KDR

EPCs. This result strengthens the hypoth-
Figure 1—Effects of sitagliptin on DPP-4 activity, progenitor cells, and soluble factors. Plasma free DPP-4 activity (A), CD34
KDR
 EPCs levels
(B), CD34
 cell levels (C), and concentrations of SDF-1 (D), MCP-1 (E), and VEGF (F) were determined at baseline and at 4 weeks in the
sitagliptin intervention group and in the control group. *P  0.05.
Sitagliptin increases endothelial progenitor cells
1608 DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 care.diabetesjournals.orgesis that sitagliptin modulates EPCs
through the SDF-1/CXCR4 axis.
This pilot trial was small and not ran-
domized, and there was a relatively high
drop-outrate.Thus,thisancillaryeffectof
sitagliptin might have favorable cardio-
vascularimplicationsbutneedstobecon-
ﬁrmed in larger and longer outcome
studies.
Acknowledgments— No potential conﬂicts
of interest relevant to this article were
reported.
G.P.F. designed the study, recruited pa-
tients, collected and analyzed data, and wrote
the manuscript. E.B. performed ﬂow cytom-
etry experiments and analyzed data. M.A. and
L.M. performed soluble factor measurements
and enzyme activity. V.F. and S.d.K. contrib-
utedtopatients’recruitment,characterization,
and data collection. C.A. standardized and su-
pervised the ﬂow cytometry protocols and in-
terpreted data. A.T. supervised and reviewed
the project. A.A. provided funds, interpreted
results, and wrote the manuscript.
References
1. Fadini GP, Agostini C, Sartore S, Avogaro
A. Endothelial progenitor cells in the nat-
uralhistoryofatherosclerosis.Atheroscle-
rosis 2007;194:46–54
2. Fadini GP, Sartore S, Albiero M, Baesso I,
Murphy E, Menegolo M, Grego F, Vigili
de Kreutzenberg S, Tiengo A, Agostini C,
Avogaro A. Number and function of en-
dothelial progenitor cells as a marker of
severity for diabetic vasculopathy. Arte-
rioscler Thromb Vasc Biol 2006;26:2140–
2146
3. Werner N, Kosiol S, Schiegl T, Ahlers P,
Walenta K, Link A, Bo ¨hm M, Nickenig G.
Circulating endothelial progenitor cells
andcardiovascularoutcomes.NEnglJMed
2005;353:999–1007
4. Fadini GP, de Kreutzenberg S, Agostini
C, Boscaro E, Tiengo A, Dimmeler S,
Avogaro A. Low CD34 cell count and
metabolic syndrome synergistically in-
crease the risk of adverse outcomes. Ath-
erosclerosis 2009;207:213–219
5. Fadini GP, Sartore S, Agostini C, Avogaro
A. Signiﬁcance of endothelial progenitor
cells in subjects with diabetes. Diabetes
Care 2007;30:1305–1313
6. Proost P, Struyf S, Schols D, Durinx C,
Wuyts A, Lenaerts JP, De Clercq E, De
Meester I, Van Damme J. Processing by
CD26/dipeptidyl-peptidase IV reduces
thechemotacticandanti-HIV-1activityof
stromal-cell-derived factor-1alpha. FEBS
Lett 1998;432:73–76
7. Ceradini DJ, Kulkarni AR, Callaghan MJ,
Tepper OM, Bastidas N, Kleinman ME,
Capla JM, Galiano RD, Levine JP, Gurtner
GC.Progenitorcelltrafﬁckingisregulated
by hypoxic gradients through HIF-1 in-
duction of SDF-1. Nat Med 2004;10:
858–864
8. Fadini GP, Boscaro E, de Kreutzenberg S,
Agostini C, Seeger F, Dimmeler S, Zeiher
A, Tiengo A, Avogaro A. Time course and
mechanisms of circulating progenitor cell
reduction in the natural history of type 2
diabetes. Diabetes Care 2010;33:1097–
1102
9. Fadini GP, Miorin M, Facco M, Bonamico
S, Baesso I, Grego F, Menegolo M, de
Kreutzenberg SV, Tiengo A, Agostini C,
Avogaro A. Circulating endothelial pro-
genitor cells are reduced in peripheral
vascular complications of type 2 diabetes
mellitus. J Am Coll Cardiol 2005;45:
1449–1457
10. MakinoH,OkadaS,NagumoA,Sugisawa
T, Miyamoto Y, Kishimoto I, Kikuchi-
Taura A, Soma T, Taguchi A, Yoshimasa
Y. Decreased circulating CD34 cells are
associated with progression of diabetic
nephropathy. Diabet Med 2009;26:171–
173
11. Fadini GP, Sartore S, Schiavon M, Albiero
M, Baesso I, Cabrelle A, Agostini C,
Avogaro A. Diabetes impairs progenitor
cell mobilisation after hindlimb isch-
aemia-reperfusion injury in rats. Diabeto-
logia 2006;49:3075–3084
12. ZarubaMM,TheissHD,VallasterM,Mehl
U, Brunner S, David R, Fischer R, Krieg L,
Hirsch E, Huber B, Nathan P, Israel L,
Imhof A, Herbach N, Assmann G, Wanke
R, Mueller-Hoecker J, Steinbeck G, Franz
WM. Synergy between CD26/DPP-IV in-
hibition and G-CSF improves cardiac
function after acute myocardial infarc-
tion. Cell Stem Cell 2009;4:313–323
13. Humpert PM, Neuwirth R, Battista MJ,
Voronko O, von Eynatten M, Konrade I,
Rudofsky G, Jr, Wendt T, Hamann A,
Morcos M, Nawroth PP, Bierhaus A.
SDF-1 genotype inﬂuences insulin-de-
pendent mobilization of adult progenitor
cells in type 2 diabetes. Diabetes Care
2005;28:934–936
14. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz
SS, Drucker DJ, Husain M. Cardioprotec-
tive and vasodilatory actions of glucagon-
like peptide 1 receptor are mediated
through both glucagon-like peptide 1
receptor-dependent and -independent
pathways. Circulation 2008;117:2340–
2350
15. Aicher A, Heeschen C, Mildner-Rihm C,
Urbich C, Ihling C, Technau-Ihling K,
Zeiher AM, Dimmeler S. Essential role of
endothelial nitric oxide synthase for mo-
bilization of stem and progenitor cells.
Nat Med 2003;9:1370–1376
Fadini and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1609